What is the debt of Arvinas this year?
Arvinas has a debt level of -310.9 USD this year.
Arvinas Debt 2024
Arvinas Debt
-310.9 USD
Ticker
ARVN
ISIN
US04335A1051
WKN
A2N6VP
In 2024, Arvinas's total debt was -310.9 USD, a 287.17% change from the -80.3 USD total debt recorded in the previous year.
Arvinas Aktienanalyse
What does Arvinas do?
Arvinas Inc. is a biopharmaceutical company based in New Haven, Connecticut, USA. It was founded in 2013 by Dr. Craig Crews, who also serves as a scientific advisor to the company. The company's mission is to develop innovative therapies based on Proteolysis-Targeting Technology (PROTAC). This technology uses artificially engineered molecules to identify and mark specific proteins in the body, which are then degraded by the body's own enzymes. This approach can treat diseases caused by misfolded or overexpressed proteins. Arvinas' business model is to develop multiple drug candidates based on this platform. The company collaborates with leading academic institutions and biotechnology companies to identify targets that can be reached using PROTAC technology. Additionally, the company has a proprietary pipeline of drug candidates in various stages of clinical development. Arvinas operates in several therapeutic areas, including cancer, immunology, and metabolic disorders. Their drug candidates include ARV-110, a PROTAC targeting the androgen receptor protein (AR), which is a potential therapy for patients with resistant prostate cancer. Similarly, Arvinas' other drug candidates target specific proteins associated with certain diseases. Another drug from the company is ARV-471, an orally administered degrader targeting the estrogen receptor alpha (ERa), which plays a role in breast cancer. ARV-471 is a potential therapy for patients with rare subtypes of breast cancer. Arvinas also has partnerships in various areas of drug development. For example, in collaboration with Pfizer, they are developing ARV-411, a PROTAC targeting the menin-1 protein, which is involved in acute myeloid leukemia. Arvinas also has a partnership with Genentech, a subsidiary of Roche, for the use of PROTAC in the treatment of cancer. Overall, Arvinas is an innovative biopharmaceutical company based on Proteolysis-Targeting Technology, focusing on the development of comprehensive therapeutic approaches. With numerous partnerships and a diverse pipeline, the company is well-positioned to play a significant role in drug development. Arvinas ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Arvinas's Debt Structure
Arvinas's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Arvinas's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Arvinas’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Arvinas’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Arvinas stock
What was the debt of Arvinas compared to the previous year?
The debt of Arvinas has increased by 287.17% compared to the previous year increased.
What are the consequences of high debt for investors in Arvinas?
High debt can pose a risk for investors of Arvinas, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Arvinas?
Low debt means that Arvinas has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Arvinas affect the company?
An increase in debt of Arvinas can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Arvinas affect the company?
A reduction in debt of Arvinas can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Arvinas?
Some factors that can influence the debt of Arvinas include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Arvinas so important for investors?
The debts of Arvinas are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Arvinas take to change the debt?
To change the debt, Arvinas can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Arvinas pay?
Over the past 12 months, Arvinas paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arvinas is expected to pay a dividend of 0 USD.
What is the dividend yield of Arvinas?
The current dividend yield of Arvinas is .
When does Arvinas pay dividends?
Arvinas pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Arvinas?
Arvinas paid dividends every year for the past 0 years.
What is the dividend of Arvinas?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Arvinas located?
Arvinas is assigned to the 'Health' sector.
Wann musste ich die Aktien von Arvinas kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Arvinas from 12/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.
When did Arvinas pay the last dividend?
The last dividend was paid out on 12/5/2024.
What was the dividend of Arvinas in the year 2023?
In the year 2023, Arvinas distributed 0 USD as dividends.
In which currency does Arvinas pay out the dividend?
The dividends of Arvinas are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Arvinas
Our stock analysis for Arvinas Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arvinas Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
